PepGen to Participate in the Leerink Global Healthcare Conference
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Key Terms
oligonucleotide therapiesmedical
Short pieces of genetic material designed to change how a specific gene behaves, acting like a targeted instruction or patch that can block, boost, or reroute a faulty cellular message. Investors care because these therapies promise highly specific treatments for diseases with unmet needs, which can command premium pricing and rapid value creation, but they also carry scientific, regulatory, manufacturing and patent risks that affect potential returns.
neuromuscularmedical
Relating to the connection and interaction between nerves and muscles, neuromuscular describes how signals from the nervous system make muscles move and function. For investors, neuromuscular issues and treatments matter because they drive demand for drugs, devices and diagnostic tests, shape development timelines and regulatory risks, and can change long-term revenue prospects in healthcare—think of it like the wiring and motors in a machine where problems or fixes affect overall performance and value.
neurologicalmedical
Relating to the nervous system — the brain, spinal cord and the network of nerves that control thought, movement and bodily functions. For investors, the word signals that a drug, device or test targets complex circuitry whose successes or failures can sharply affect clinical trial outcomes, regulatory approval and long-term sales potential, much like fixing or breaking the main electrical wiring in a building impacts all downstream systems.
BOSTON--(BUSINESS WIRE)--
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that James McArthur, PhD, President and CEO of PepGen, will participate in a fireside chat at the Leerink Global Healthcare Conference on Tuesday, March 10, 2026 at 3:00 p.m. ET in Miami, Florida.
A webcast of the event will be available on the "Events & Presentations" page within the Investors section of the PepGen website at https://investors.pepgen.com/. A replay of the webcast will be available on the PepGen website for 90 days following the presentation date.
About PepGen
PepGen is a clinical-stage biotechnology company advancing the next-generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases. PepGen’s Enhanced Delivery Oligonucleotide (EDO) platform is founded on over a decade of research and development and leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Using these EDO peptides, PepGen is generating a pipeline of oligonucleotide therapeutic candidates that are designed to target the root cause of serious diseases.
